Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases

European Journal of Clinical Investigation

Volumn 33, Issue 2, 2003, Pages 99-105

  De La Pena Diaz A ^a   Cardoso Saldana G ^a   Zamora Gonzalez J ^a   Barinagarrementeria, F ^b   Izaguirre, R ^a   Loyau, S ^c   Angles Cano E ^c,d  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c INSERM   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

Cerebrovascular disease; Fibrinolysis; Ischaemic cardiopathy; Lipoprotein(a); Plasminogen

Indexed keywords

APOLIPOPROTEIN A; FIBRIN; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY; PLASMIN; PLASMINOGEN;

ARTICLE; ATHEROGENESIS; BINDING COMPETITION; BRAIN ARTERY; BRAIN DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; FIBRINOLYSIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

ADULT; APOLIPOPROTEINS A; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; FEMALE; FIBRIN; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLASMIN; PLASMINOGEN; PROTEIN BINDING; PROTEIN ISOFORMS;

EID: 0345505294     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01114.x     Document Type: Article

References (35)

1. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5.
2. Kraft HG, Menzel HJ, Hoopichler F, Vogel W, Uterman G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. J Clin Invest 1989;383:137-42.
3. Kostner GM, Wo X, Frank S, Kostner K, Zimmermann R, Steyrer E. Metabolism of Lp (a): assembly and excretion. Clin Genet 1997;52:347-54.
4. Berg K. Lp (a) lipoprotein: an over-view. Chem Phys Lipids 1992;67/68:9-18.
5. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;300:132-7.
6. Guevara J Jr, Knapp RD, Honda S, Northup SR, Morrisett JD. A structural assessment of the apo (a) protein of human lipoprotein (a). Proteins 1992;12:188-99.
7. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp (a) glycoprotein phenotypes: Inheritance and relation to Lp (a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458-65.
8. Hervio L, Brunner C, Sorell L, Kang C, Muller H, Anglés-Cano E. Effect of plasminogen activators on human recombinant apolipoprotein (a) having the plasminogen activation cleavage site. Biochim Biophys Acta 1999;1434:124-34.
9. Rouy D, Koschinsky ML, Fleury V, Chapman MJ, Anglés-Cano E. Biochemistry 1992;31:6333-9.
10. Hervio L, Durlach V, Girard-Globa A, Anglés-Cano E. Multiple binding with identical linkage. a mechanism that explains the effect of lipoprotein (a) on fibrinolysis. Biochemistry 1995;34:13353-8.
11. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-9.
12. Anglés-Cano E, de la Peña-Diaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein (a). Ann NY Acad Sci 2001;936:261-75.
13. De la Peña-Díaz A, Izaguirre Avila R, Anglés-Cano E, Lipoprotein Lp. (a) and atherothrombotic disease. Arch Med Res 2000;31:353-9.
14. Sangrar W, Gabel BR, Boffa MB, Walker JB, Hancock MA, Marcovina SM, et al. The solution phase interaction between apolipoprotein (a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry 1997;36:10353-63.
15. Caplice NM, Panetta C, Peterson TE, Kleppe L.S, Mueske CS, Kostner GM, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitors: a novel link between lipoproteins and thrombosis. Blood 2001;98:2980-7.
16. Dahlen GH, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 1997;52:272-80.
17. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990;301:1248-51.
18. Dahlen GH. Lp (a) Lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-26.
19. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Lab Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem 2000;46:1956-67.
20. Soulat T, Loyau S, Baudouin V, Maisonneuve L, Hurtaud-Roux MF, Schlegel N, et al. Effect of individual plasma lipoprotein (a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome. Arterioscler Thromb Vasc Biol 2000;20:575-84.
21. Fleury V, Anglés-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: role of carboxy-terminal lysines. Biochemistry 1991;30:7630-8.
22. Anglés-Cano E. A spectrophotometric solid-phase fibrin tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin affinity tissue plasminogen activators. Anal Biochem 1986;153:201-10.
23. Sorell L, Rojas G, Rodriguez M, Ramos C, Torres L, Torres MB. A sandwich ELISA based on anti-apo (a) and anti-apo B monoclonal antibodies for lipoprotein (a) measurement. Clin Chim Acta 1995;236:59-70.
24. Anglés-Cano E, Loyau S, Cardoso-Saldaña G, Courdec R, Gillery R. A novel kringle-4 number based recombinant apo (a) standard for human apo (a) phenotyping. J Lipid Res 1999;40:354-9.
25. Hervio L, Chapman MJ, Thillet J, Loyau S, Anglés-Cano E. Does apolipoprotein (a) heterogeneity influence lipoprotein (a) effects on fibrynolisis? Blood 1993;82:392-7.
26. Hervio L, Girard-Globa A, Durlach V, Anglés-Cano E. The antifibrinolytic effect of lipoprotein (a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein (a) isoforms and their affinity for fibrin. Eur J Clin Invest 1996;26:411-7.
27. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, et al. Role of lipoprotein (a) and apolipoprotein (a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999;100:1154-60.
28. Hachinski V, Graffagnino C, Beaudry M, Bernier G, Buck C, Donner A, et al. Lipids and stroke: a paradox resolved. Arch Neurol 1996;53:303-8.
29. Glader CA, Stegmayr B, Boman J, Stenlund H, Weinehall L, Hallmans G, et al. Chlamydia pneumoniae antibodies and high lipoprotein (a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. Stroke 1999;30:2013-8.
30. Alfthan G, Pekkanen J, Jauhaiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
31. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein (a) and the risk of future stroke. JAMA 1995;273:1269-73.
32. Wityk RJ, Kittner SJ, Jenner JL, Hebel JR, Epstein A, Wozniak MA, et al. Lipoprotein (a) and the risk of ischemic stroke in young women. Atherosclerosis 2000;150:389-96.
33. Soulat T, Loyau S, Baudouin V, Durlach V, Gillery P, Roselyne G, et al. Evidence that modifications of Lp (a) in vivo inhibit plasmin formation on fibrin. Thromb Haemostas 1999;82:121-7.
34. Jürgens G, Taddei-Peters W, Költringer P, Petek W, Chen Q, Greilberger J, et al. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26:1841-8.
35. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555.